Abstract
Background Mucosal–associated invariant T (MAIT) cells are unconventional innate-like T cells abundant in mucosal tissue of humans, and associated with protective responses to microbial infections. MAIT cells have capacity for rapid effector function, including the secretion of cytokines and cytotoxic molecules. However, limited information is available regarding the activity of MAIT cells in mucosal vaccine-mediated immune responses in humans.
Methods We enrolled healthy adults who received a course of oral live-attenuated S. Typhi strain Ty21a vaccine and collected peripheral blood samples pre-vaccination, and at 7 days and one month post-vaccination. We used flow cytometry, cell migration assays, and tetramer decay assay to assess MAIT cell responses.
Results We show that following vaccination, circulating MAIT cells are decreased in frequency but have increased activation markers. Post-vaccine timepoints had higher levels of MAIT cells expressing gut-homing marker integrin α4β7 and chemokine receptor CCR9, suggesting the potential of MAIT cells to migrate to mucosal sites. While we found higher frequencies of TNF-α expression on MAIT cells post-vaccination, we did not find significant differences in expression of other effector molecules, TCR avidity, or cell migration.
Conclusions We show how MAIT cell immune responses are modulated post-vaccination against S.Typhi. This study contributes to our understanding of MAIT cells’ potential role in oral vaccination against bacterial mucosal pathogens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the National Institutes of Health (AI130378 to D.T.L.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Utah gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
